ClinicalTrials.gg
CompletedNCT01585649Updated May 18, 2016

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

A Phase 1 interventional study of Lipegfilgrastim in Ewing Family of Tumors, Rhabdomyosarcoma, sponsored by Merckle GmbH. Completed at 18 sites in 6 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Merckle GmbH · Phase 1, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Study summary

This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy (CTX)

02

Conditions studied

  • Ewing Family of Tumors, Rhabdomyosarcoma
03

In context

Neuroectodermal Tumors, Primitive, Peripheral

135 studies on the registry are indexed under Neuroectodermal Tumors, Primitive, Peripheral; 2 are open to participants now.

This study's enrollment of 21 is below the median of 31 across 102 interventional studies indexed under Neuroectodermal Tumors, Primitive, Peripheral.

Browse Neuroectodermal Tumors, Primitive, Peripheral studies →

Lead sponsor

Merckle GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female children and adolescents aged 2 to \<18 years
  • Written provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate
  • Able to understand and/or follow study instructions alone or with parental assistance
  • Diagnosed with the Ewing family of tumors or Rhabdomyosarcoma
  • Scheduled to receive 1 of the following CTX regimens (inpatient or outpatient)
  • For the Ewing family of tumors:

    • vincristine/ifosfamide/doxorubicin/etoposide (VIDE); with concomitant sodium 2-mercaptoethane sulfonate (MESNA) according to local standards
    • vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
  • For rhabdomyosarcoma:

    • vincristine/actinomycin/cyclophosphamide (VAC)
    • vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
  • Chemotherapy-naïve
  • Body weight ≥15 kg
  • White blood cell (WBC) count >2.5 x 109/L, (ANC) ≥1.5 x 109/L, and count ≥100 x 109/L (at screening and prior to CTX)
  • For patients aged ≥12 years, (ECOG) performance status ≤2 (See Appendix A.)
  • Fertile patients (male or female) must use highly reliable measures (i.e. two of the following: oral contraception, implants, injections, barrier contraception, and intrauterine device, or vasectomized/sterilized partners, or sexual abstinence). For purposes of this study, a fertile female patient is any female patient who has experienced menarche and who has not undergone tubal ligation.
  • Female patients who have attained menarche must have a negative urine pregnancy test at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to filgrastim, pegfilgrastim or lenograstim or other G-CSFs in clinical development within 6 months prior to the XM22 administration
  • Known to filgrastim, pegfilgrastim or lenograstim or any other G-CSF in clinical development
  • History of congenital neutropenia or cyclic neutropenia
  • Any illness or condition that in the opinion of the Investigator may affect the safety of the patient or the evaluation of any study endpoint
  • Pregnant or nursing women
  • Fertile patients who do not agree to use highly reliable measures during the entire duration of the study
  • Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow (e.g. whole pelvic radiation) for any reason, or any therapeutic radiation within the 3 weeks prior to the XM22 dose
  • Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit
  • Treatment with lithium at screening or planned during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    XM22, 100 μg/kg BW

    Drug: Lipegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration

    A total of 7 PK samples will be obtained at prespecified periods

    Time frame: 16 months

Secondary outcomes

  1. PD:Absolute Neutrophil Count

    Time frame: 16 months

07

Study locations

18 sites
  • Teva Investigational Site 0103
    Plovdiv, Bulgaria
  • Teva Investigational Site 0101
    Sofia, Bulgaria
  • Teva Investigational Site 0102
    Varna, Bulgaria
  • Teva Investigational Site 0201
    Praha 5, Czech Republic
  • Teva Investigational Site 0301
    Budapest, Hungary
  • Teva Investigational Site 0401
    Lublin, Poland
  • Teva Investigational Site 0501
    Chelyabinsk, Russian Federation
  • Teva Investigational Site 0504
    Ekaterinburg, Russian Federation
  • Teva Investigational Site 0507
    Krasnodar, Russian Federation
  • Teva Investigational Site 0505
    Moscow, Russian Federation
  • Teva Investigational Site 0506
    Moscow, Russian Federation
  • Teva Investigational Site 0508
    Moscow, Russian Federation
  • Teva Investigational Site 0502
    St. Petersburg, Russian Federation
  • Teva Investigational Site 0701
    Dnipropetrovsk, Ukraine
  • Teva Investigational Site 0705
    Donetsk, Ukraine
  • Teva Investigational Site 0702
    Kharkiv, Ukraine
  • Teva Investigational Site 0704
    Kyiv, Ukraine
  • Teva Investigational Site 0703
    Lviv, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jun 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2012
First posted
Apr 26, 2012
Start
Jul 2012
Primary completionActual
Jun 2014
CompletionActual
Apr 2015
Last update
May 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01585649
Lead sponsor
Merckle GmbH
Responsible party
Sponsor
First posted
Apr 26, 2012
Start date
Jul 2012
Primary completion
Jun 2014
Completion
Apr 2015
Last update
May 18, 2016

Study contacts

Andreas Lammerich, MD
study director · Merckle GmbH, Teva Ratiopharm
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion